Synaptic modulators
DISC1 is a leading candidate gene for schizophrenia and related disorders. It has several modes of action through protein-protein interaction at multiple cellular locations, including the synapse.
1,2 Previously, we developed and characterised a mouse line carrying an ENU-induced Disc1 missense mutation, L100P. The mice exhibit behavioural, anatomical and pharmacological phenotypes related to schizophrenia; schizophrenia-like endophenotypes, including deficits in pre-pulse inhibition, latent inhibition and working memory, and, at the molecular level, reduced DISC1-PDE4B interaction. 3 Here, we show that the L100P mutation disregulates expression of the synaptic modulators Nrxn1 and Nrxn3 at Figure 1 Map of t-values from voxel-wise analysis of rs6741892, overlaid on a sample axial magnetic resonance imaging slice at the level of the medial thalamus (z = 6 mm). Bilaterally, T-allele carriers (n = 13) have greater serotonintransporter-binding potential than AA homozygotes (n = 42). The color bar indicates the range of t-values displayed (max t = 6.56, df = 53, P = 2.3 Â 10 À8 ).
key points during development, as well as in the adult mouse. Nrxn1 is involved in maintenance of synaptic junctions and is a mediator of intracellular signalling, modulating maturation and differentiation of synapses. 4 Nrxn3 is a membrane protein involved in cell adhesion, synaptic transmission and neurotransmitter secretion. 4 Both the Neurexin gene family and DISC1 have been independently implicated in schizophrenia and autism. A missense mutation and copy number variants in NRXN1 were first linked to autism (ref. 5 and references within), and copy number variants in this gene were subsequently reported to be more abundant in schizophrenia than in controls (ref. 6 and references within). Recent pathway analysis of the genes identified by three large genome-wide association studies of bipolar disorder and schizophrenia (ISC, GAIN and WTCCC) suggested that perturbation of cell adhesion molecules may be central to development of neuropsychiatric illness and, furthermore, identified NRXN1 as being one of two genes associated in all three studies. 7 The role of DISC1 in schizophrenia and bipolar disorder is well established, 1 but a number of recent studies of autism spectrum disorders have found association between DISC1 variants and these conditions also (ref. 8 
and references within).
We used Illumina (Illumina, Essex, UK) wholegenome expression profiling of 47 000 mouse brain transcripts to compare hippocampal samples from the Disc1 L100P mutant line (n = 12) and wild-type control mice (n = 12) at 12 weeks of age. Expression of both Nrxn1 and Nrxn3 showed a modest, but significant upregulation in the L100P mutant mice compared with wild-type controls ( Figure 1a ). This was confirmed by quantitative RT-PCR analysis of both the original array RNA and an independent sample set ( Figure 1a ). This prompted us to examine Nrxn1 and Nrxn3 expression profiles across development in the L100P mutant. Expression profiles of both genes in the mutant animals differed strikingly from those observed in wildtype mice. Significant differences in expression were observed at E15, E18, P7 and adult, with the largest differences being increased expression in the L100P mutant at E15 and P7, and decreased expression at E18 (Figures 1b and c) .
It is noteworthy that the L100P Nrxn1 and Nrxn3 expression profiles differ most from the wildtype between E18, a stage of synaptic formation and neuronal maturation, and P7, when neurite outgrowth, myelination, synaptic pruning and apoptosis occur. 9 Disregulation of such key processes may lead to alterations in brain development and function. Kitamura et al. 10 showed that both Nrxn1 and Nrxn3 are synaptic activity-dependent genes; they are downregulated in the presence of the potent neurotoxin tetrodotoxin and somewhat upregulated by it's withdrawal. Taking note of the emerging evidence for a synaptic function for Disc1, 2 we hypothesise that in the developing embryo, the presence of mutant Disc1 at the synapse affects synaptic function, leading to a change in synaptic activity-mediated transcription of Nrxn1, Nrxn3 and other genes. We speculate that this change in transcription of Nrxn1 and 3 (and possibly other synaptic genes) results in altered formation and function of inhibitory and excitatory synapses during this critical developmental period.
To summarise, here we demonstrate, for the first time, that there is a DISC1-dependant mechanism for regulating neurexin gene expression. The striking disregulation of Nrxn1 expression in the L100P Disc1 mutant animals provides a first functional link between these two prominent genetic candidates for risk of schizophrenia and of autism.
Conflict of interest
The authors declare no conflict of interest. We provide independent evidence in support of a recent finding by Craddock et al. 1 that variation in g-aminobutyric acid (GABA) A receptor genes is selectively associated with one component of the bipolar disorder (BD) phenotype, that is schizophrenia-like psychotic symptoms. The support is at a system-wide level and the pattern of genetic variation was not identical to that observed in the Craddock sample.
Although the GABAergic system, the major inhibitory neurotransmission system in the central nervous system, has been implicated in the etiology of BD, genetic association findings have been inconsistent. 2 One of the most strongly associated polymorphisms in the recent Wellcome Trust Case Control Consortium genome-wide association study of BD (1868 cases, 2938 controls) 3 is located in the GABRB1 gene, which encodes the GABA A receptor b1 subunit. The consortium conducted a further analysis to reduce biological heterogeneity. In this second analysis, the strongest signal at this polymorphism was found in the subsample meeting Research Diagnostic Criteria 4 for schizoaffective, bipolar type (SABP) (n = 279). Association signals were also found in the SABP subsample at GABRA4, GABRB3, GABRA5, and GABRR3 (experiment-wide P = 6.6 Â 10
À5
). This provided strong, independent evidence in support of the hypothesis that variation in other GABA A receptor genes is associated with risk for the SABP phenotype. No association was found with schizophrenia.
We aimed to replicate these findings in our German samples using the set-based approach. A total of 682 BD inpatients, 480 schizophrenia inpatients, and 1300 controls were included. All participants had been earlier genome-wide association study genotyped 5 using the Illumina HumanHap550v3 BeadArray. These data were subjected to strict quality control procedures, as described elsewhere. 5 Patients had been diagnosed according to DSM-IV 6 and the BD sample was divided into SABP (n = 352) and non-SABP (n = 330) cases according to Research Diagnostic Criteria on the basis of the Operational Criteria Checklist (OPCRIT v3.32). 7 Using Research Diagnostic Criteria, SABP was scored as being present if one or more of the 23 OPCRIT items (no. 54-77) indicating the life-time presence of abnormal beliefs, ideas, or perceptions occurred.
We searched Entrez Gene (NCBI build 36.3: http:// www.ncbi.nlm.nih.gov/gene/) for single-nucleotide polymorphisms across the 19 GABA A receptor genes and identified 362 that were within our genome-wide association study dataset. To reduce redundancy, we used the HaploView 8 (v4.1) implementation of de Bakker's tagger with r 2 set to 0.8 and obtained a final reduced marker set of 276 single-nucleotide polymorphisms. Table 1 shows their distribution across the 19 GABA A receptor genes.
We used the set-based test (with default options and 10 6 permutations), as implemented in PLINK 9 (v1.0.6), to test for association between the SABP cases and the whole set of these GABA A receptor gene variants (that is a system-wide test), as described by Craddock et al.
1
We also performed gene-wide association testing for each gene.
In a system-wide replication of the earlier report, we observed significant association with the SABP cases when compared with controls (P = 0.00315). Gene-wide significant associations were observed for GABRA1 (P = 0.01647), GABRB2 (P = 0.00022), and GABRG2 (P = 0.01364). This combination of genes codes for the major GABA A receptor subunit in the mammalian brain. 2 Again replicating the earlier
